PTC Therapeutics PTCT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $272.55M+65.5% | $164.68M-22.0% | $211.01M+18.0% | $178.88M-84.8% | $1.18B+452% | ||
| $100.87M-24.2% | $133.13M+32.9% | $100.16M-11.4% | $112.99M+3.7% | $108.97M-12.7% | ||
| $86.18M-11.0% | $96.87M+15.3% | $84.05M-1.4% | $85.26M+5.3% | $80.96M-4.4% | ||
| $11.58M+23.9% | $9.35M+24.1% | $7.53M+85.5% | $4.06M+6.9% | $3.8M+14.8% | ||
| $227.59M-3.6% | $236.03M+13.5% | $207.99M-2.7% | $213.83M+3.9% | $205.87M-45.2% | ||
| $227.59M-3.6% | $236.03M+13.5% | $207.99M-2.7% | $213.83M+3.9% | $205.87M-45.2% | ||
| $44.96M— | $0-100% | $3.02M+109% | -$34.96M-104% | $970.23M+697% | ||
| 16.5%+16.5pp | 0%-1.4pp | 1.4%+21.0pp | -19.5%-102pp | 82.5%+159pp | ||
| -$49.03M+11.2% | -$55.19M-69.3% | -$32.59M-7.4% | -$30.36M+11.0% | -$34.09M+17.0% | ||
| $1.61M+113% | -$12.55M-293% | $6.5M+213% | -$5.74M+9.0% | -$6.31M-171% | ||
| -$2.46M— | —— | -$23.07M+67.5% | -$71.05M-108% | $929.83M+1,082% | ||
| $347K— | —— | -$38.97M-528% | -$6.2M-110% | $63.27M— | ||
| -$2.81M— | —— | $15.9M+125% | -$64.85M-107% | $866.56M+1,415% | ||
| -1%— | —— | 7.5%+43.8pp | -36.3%-110pp | 73.7%+105pp | ||
| -$0.03— | —— | $0.20+124% | -$0.83-108% | $10.04+1,281% | ||
| -$0.03— | —— | $0.20+124% | -$0.83-107% | $11.09+1,405% | ||
| 82.5M-6.6% | 88.3M+1.4% | 87.1M+11.5% | 78.2M-9.5% | 86.4M+12.4% | ||
| 82.5M+3.8% | 79.5M+1.4% | 78.5M+0.4% | 78.2M0.0% | 78.1M+1.7% | ||
| $28.03M+303% | $6.95M-56.0% | $15.78M+38.2% | $11.42M-11.2% | $12.86M-21.0% | ||
| -$927K-109% | $10.28M+2,277% | -$472K-377% | -$99K-28.6% | -$77K— | ||
| -$49.03M+11.2% | -$55.19M-69.3% | -$32.59M-7.4% | -$30.36M+11.0% | -$34.09M+17.0% | ||
| $11.58M+23.9% | $9.35M+24.1% | $7.53M+85.5% | $4.06M+6.9% | $3.8M+14.8% | ||
| —— | —— | —— | —— | $800K-92.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.61M+113% | -$12.55M-293% | $6.5M+213% | -$5.74M+9.0% | -$6.31M-171% | ||
| $272.55M+65.5% | $164.68M-22.0% | $211.01M+18.0% | $178.88M-84.8% | $1.18B+452% | ||
| $44.96M— | $0-100% | $3.02M+109% | -$34.96M-104% | $970.23M+697% | ||
| $60.37M+368% | $12.9M-8.7% | $14.13M+152% | -$27.37M-103% | $977.45M+728% | ||
| $60.37M+368% | $12.9M-8.7% | $14.13M+152% | -$27.37M-103% | $977.45M+728% | ||
| 22.2%+14.3pp | 7.8%+1.1pp | 6.7%+22.0pp | -15.3%-98.4pp | 83.1%+156pp | ||
| $44.96M— | $0-100% | $3.02M+109% | -$34.96M-104% | $970.23M+697% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is PTC Therapeutics's revenue?
- PTC Therapeutics (PTCT) generated $827.1M in revenue over the trailing twelve months, down 53.3% year over year.
- Is PTC Therapeutics profitable?
- PTC Therapeutics reported $814.8M in net income over the trailing twelve months, a 42.3% net margin.
- What are PTC Therapeutics's profit margins?
- Gross margin is 96.0% and operating margin is 1.6%, with a 42.3% net margin.
- What is PTC Therapeutics's earnings per share?
- PTC Therapeutics's diluted EPS over the trailing twelve months is $9.38.
- Where does PTC Therapeutics's income statement data come from?
- Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
